This Week’s CGT News: CRISPR Hits Phase 3 Milestone
May 4, 2026
Intellia’s one-time HAE therapy delivers strong results as Cabaletta strikes CAR-T manufacturing deal
6 min read
False
Advertisement
Cell & Gene
Manufacturing Viral Vectors for the Next Phase of CGT
April 30, 2026
As the sector matures, scalable vector production and robust analytical control are becoming essential to clinical and commercial success
7 min read
Roving Reporter Asks: What Is Your View on the Takeda “U-turn”?
April 29, 2026
IBTV speaks with industry leaders at the 2025 Meeting on the Mesa to unpack reactions to Takeda’s strategic shift.
Roving Reporter Asks: What Was the Biggest Development in CGT of 2025?
April 22, 2026
IBTV speaks with industry leaders at the 2025 Meeting on the Mesa to uncover the year’s defining breakthroughs
10 min read
This Week’s CGT News: New FDA Genome Editing Guidance
April 20, 2026
Our latest roundup highlights tighter FDA expectations for genome editing safety, advances in CRISPR precision and delivery, and continued momentum for off-the-shelf CAR-T
4 min read
Cell and Gene Roundup: CAR T Breaks New Ground
April 15, 2026
A campus-built therapy enters clinical trials as researchers refine gene editing and uncover new ways to control gene expression
5 min read
FDA Fast-Tracks Off-the-Shelf CAR-T for Aggressive T-Cell Cancers
April 14, 2026
WashU Medicine-developed WU-CART-007 has received Breakthrough Therapy designation after early clinical results in relapsed or refractory T-cell leukemias and lymphomas.
1 min read
CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease
April 13, 2026
An investigational Cas12a-edited stem cell treatment sharply boosted HbF and largely eliminated vaso-occlusive crises in an early trial
2 min read
New Iron-Tracking Tool Could Boost Cartilage Regeneration Therapies
April 10, 2026
MIT-led team develops rapid, non-destructive method to predict stem cell quality during manufacturing
1 min read
Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda
April 9, 2026
New modeling study shows curative treatments may be viable in low-income settings if costs are scaled and societal benefits included
1 min read
